|Date||December 24, 2020 – present|
|Cause||COVID-19 pandemic in Mexico|
|Part of a series on the|
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
By September 25, 2021, Mexico had administered a total of 97,523,789 doses (74.87 vaccine doses per 100 people), with 54,275,054 residents having received at least one dose and 43,248,659 residents fully vaccinated.Mexico has purchased 310.8 million vaccines doses which covers 141.2% of its population.
Wealthy Mexicans were reported to travel to the neighbouring United States for receiving their vaccinations.In March, the White House announced that four million of doses of COVID-19 vaccines manufactured in the United States will be sent to Mexico.
In a survey conducted in March 2021, 52% of the Mexicans said that they were willing to get vaccinated against COVID-19, 20% said they were not sure and 28% said they would not get vaccinated.
On 20 April 2021, President López Obrador televised himself receiving the AstraZeneca vaccine.
The National vaccination plan against COVID-19 has been planned as below in Mexico:
NOT UPDATED SINCE APRIL 2021 - Mexico has contracted 79.4 million doses of the AstraZeneca/Oxford vaccine, 35 million doses of the CureVac vaccine, 22 million doses of the Johnson & Johnson vaccine, 39 million doses of the Moderna vaccine, 10 million doses of the Novavax vaccine, 34.4 million doses of the BioNTech/Pfizer vaccine, 24 million doses of the Sputnik V vaccine, 35 million doses of Convidecia, 12 million doses of the Sinopharm BIBP vaccine and 20 million doses of CoronaVac.3,305,000 doses of the AstraZeneca/Oxford vaccine have been delivered through the COVAX mechanism, a global initiative that aims at equitable distribution for Covid-19 vaccines. Moreover, the United States have sent 2.5 million doses of the AstraZeneca/Oxford vaccine to Mexico.
The following vaccines are authorized by the Mexican government for use against COVID-19 (approval date in parentheses):
|Pfizer–BioNTech||December 11, 2020||December 24, 2020|
|Oxford–AstraZeneca||January 4, 2021||Yes|
|Convidecia||February 8, 2021||Yes|
|Sputnik V||February 9, 2021||Yes|
|CoronaVac||February 9, 2021||Yes|
|Covaxin||April 6, 2021||Not yet|
|Janssen||May 27, 2021||June 17, 2021|
|Moderna||August 17, 2021||Yes|
|Sinopharm BIBP||August 27, 2021||Not yet|
|Abdala||December 28, 2021||Not yet|
|Vaccine||Type (technology)||Phase I||Phase II||Phase III|
|GRAd-COV2||Viral vector||Completed||Completed||In progress|
|Patria||Viral vector||Completed||In progress||Not yet|
The Secretary of Foreign Affairs, Marcelo Ebrard, released the details of the agreement between the government of Mexico, Argentina, the pharmaceutical company AstraZeneca and the Carlos Slim Foundation to produce and distribute the vaccine developed by the University of Oxford.
The strategy to distribute the vaccine in Latin America, the product manufactured in the Argentine mAbxience laboratory, will be transferred to the Mexican facilities of the Liomont laboratory, which will be in charge of completing the stabilization, manufacturing and packaging process of the vaccine. The COVID-19 vaccine from the pharmaceutical company CanSino Biologics will be packaged in Querétaro, after the company requested from COFEPRIS, authorization for its emergency use of its vaccine.
The COVID-19 pandemic in Panama is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Panama on 9 March 2020. One of the dead was a 64-year-old male, who also suffered from complications of diabetes and pneumonia. Of those infected, 83 were admitted to hospital. The infected individuals belong to the 29-59 age group and had each recently travelled abroad. A 13-year-old girl died of COVID-19 on 23 March.
The COVID-19 pandemic in Uruguay is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The first cases in Uruguay were reported on 13 March 2020 by the Ministry of Public Health. The early cases were imported from Italy and Spain, with some local transmissions.
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO). It is one of the three pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well logistics, country readiness and in-country delivery.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Peru is the national vaccination strategy to protect the population against SARS-CoV-2 employing vaccines developed for the COVID-19 pandemic in Peru. Vaccination began on 9 February 2021, after three days of arrival of first vaccines. On a nation message, the head of state Francisco Sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel.
On 29 January 2021, Algeria launched a coronavirus vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The COVID-19 virus was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
COVID-19 vaccination programs have begun in many countries and territories in Africa. In June 2021, the World Health Organization predicted that 47 of Africa's 54 nations would fall short of the aim of vaccinating 10% of their people by September 2021. In June, Africa accounted for fewer than 1% of worldwide vaccine doses delivered.
COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.
Vaccination in Mexico includes the use of vaccines in advancing public health. Mexico has a multi-year program for immunisation of children. The immunisation of children is fully covered by the government of Mexico. Mexico has an adverse events committee to monitor the adverse effects of vaccination as well as a standing technical advisory group on immunization.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
The COVID-19 vaccination campaign in Brazil is an ongoing mass immunization campaign for the COVID-19 pandemic in Brazil. It started on January 17, 2021, when the country had 210 thousand deaths.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
The COVID-19 vaccination in Spain is the national vaccination strategy started on the 27th of December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in the Democratic Republic of the Congo is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.